Q. A researcher is studying the pathophysiology of cardiomyopathy on guinea pig animal models. He develops a chemical compound that directly disrupts the hydrophobic pockets within the protein connecting the heavy sarcomere chain to the Z-protein. Which of the following clinical manifestations is expected as a direct result of such an intervention?